SymBio Pharmaceuticals

TYO: 4582

JPY14106m market cap

JPY579 last close

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Investment summary

In an unfortunate turn, SymBio has run into some quality control issues with its shipments of Treakisym from Astellas. During Q219, the company found an unacceptable level of ‘foreign substance or visual defects’ in the shipments of drugs, which had to be returned. The company revised its sales estimates down by a third (to ¥3.0bn from ¥4.5bn) due to the expected short supply.

Y/E Dec
Revenue (¥m)
PBT (¥m)
EPS (fd) (¥)
P/E (x)
P/CF (x)
2017A 3444.0 (3917.0) (3977.0) (319.0) N/A N/A
2018A 3836.0 (2621.0) (2749.0) (166.0) N/A N/A
2019E 3009.0 (3732.0) (3847.0) (171.0) N/A N/A
2020E 4043.0 (5140.0) (5143.0) (211.0) N/A N/A
Last updated on 13/09/2019
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Last updated on 13/09/2019
Share price graph
Balance sheet
Forecast net cash (¥m) 3728
Forecast gearing ratio (%) N/A
Price performance
Actual (0.3) (18.7) 18.7
Relative* (8.0) (22.1) 26.0
52-week high/low ¥1088.0/¥488.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO
Kenji Murata Corporate Officer

Content on SymBio Pharmaceuticals